3Pinzani M,Milanis,de Franco R,et al.Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated heapatic stellate cells[J].Gastroenterology,1996,110(4):534 - 548.
4Bauer M,Zhang JX,Buer I,et al.ET-1 induced alternations of hepatic microcirculates:sinusoidal and extrasinusoidal sites of action[J].Am J Physiol,1994,267 (1 pt 1) G143.
5Rockey DC,Weisiger RA.Endothlin induced sontractility of stellate cells from normal and cirrhotic rat liver:implication for regulation of portal pressure and resistance[J].Hepatology,1996,24 (2):233-240.
6Bendtsen F,Schifter S,et al.Increased circulating calicitonin gene related peptide in cirrhosis[J].J Hepatol,1991,12 (1):118 -123.
7Moll-Kaufmarm C.Sumanovsdilalation in normal and portal hypertensive rats:role of nitric oxide and calcitonin gene-relatred peptide[J].J Hepato,1998,28 (6):1031-1066.
1Ferre N. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage[Jl. Clin Chem, 2002, 48:261-268.
2National Committee for Clinical Laboratory Standards.Precision performance of cli-nical chemistry devices[ S].edition. Tentative guideline, NCCLS, EP5-T2, 1992.
3National Committee for Clinical Laboratory Standards.Precision performance of cli-nical chemistry devices[ S].edition. Tentative guideline, NCCLS, EP6, 1991.
4Banka CL. High density lipoprotein and lipoprotein oxidation[J ]. Curr Opin Lipidol, 1996, 7 : 139-142.
5Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein[J ]. FEBS Lett, 1991, 286 : 152-154.
6Mackness B,Durrington PN,Mackness MI.The paraoxonase gene family and coronary heart disease.Curr Opin Lipidol,2002,13:357-362.
7Sozmen EY,Mackness B,Sozmen B,et al.Effect of organophosphate intoxication on human serum paraoxonase.Hum Exp Toxicol,2002,21:247-252.
8Leviev I,Poirier O,Nicaud V,et al.High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients.Atherosclerosis,2002,161:463-467.
9Paragh G,Asztalos L,Seres I,et al.Serum paraoxonase activity changes in uremic and kidney-transplanted patients.Nephron,1999,83:126-131.
10Hasselwander O,Savage DA,McMaster D,et al.Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients.Kidney Int,1999,56:289-298.
